Radioimmunotherapy using 131I-rituximab in patients with advanced stage B-cell non-Hodgkin's lymphoma: Initial experience

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 32, Issue 10, 2005, Pages 1225-1233

  Bienert, Maren ^a   Reisinger, Ingrid ^a   Srock, Stefanie ^a   Humplik, Beatrice I ^a   Reim, Christel ^a   Kroessin, Thomas ^a   Avril, Norbert ^a   Pezzutto, Antonio ^a   Munz, Dieter L ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

131I rituximab; Non Hodgkin's lymphoma; Radioimmunotherapy

Indexed keywords

ANTIBIOTIC AGENT; CD20 ANTIBODY; CYCLOPHOSPHAMIDE; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; IODINE 131; LACTATE DEHYDROGENASE; PREDNISONE; RADIOPHARMACEUTICAL AGENT; RITUXIMAB; RITUXIMAB I 131; UNCLASSIFIED DRUG; VINCRISTINE; 131I RITUXIMAB; 131I-RITUXIMAB; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; B LYMPHOCYTE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DEATH; DOSIMETRY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; ERYTHROCYTE; ERYTHROCYTE TRANSFUSION; FEMALE; FEVER; FOLLICULAR LYMPHOMA; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN CELL; ISOTOPE LABELING; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKOCYTE; MALE; MANTLE CELL LYMPHOMA; MULTIMODALITY CANCER THERAPY; NONHODGKIN LYMPHOMA; PANCYTOPENIA; PNEUMONIA; RADIATION DOSE; RADIOIMMUNOTHERAPY; SALVAGE THERAPY; THROMBOCYTE; THROMBOCYTE TRANSFUSION; TREATMENT OUTCOME; CLINICAL TRIAL; HOSPITALIZATION; METHODOLOGY; MIDDLE AGED; PILOT STUDY; RADIATION INJURY; TUMOR RECURRENCE;

ADULT; AGED; ANTIBODIES, MONOCLONAL; FEMALE; HUMANS; LYMPHOMA, B-CELL; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PILOT PROJECTS; RADIATION INJURIES; RADIOIMMUNOTHERAPY; RADIOPHARMACEUTICALS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 25144471131     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-005-1770-7     Document Type: Article

References (34)

1. Armitage JO. Treatment of non-Hodgkin's lymphoma. N Engl J Med 1993;328:1023-30.
2. Gallagher CJ, Gregory WM, Jones AE, Stansfeld AG, Richards MA, Dhaliwal HS, et al. Follicular lymphoma: prognostic factors for response and survival. J Clin Oncol 1986;4:1470-80.
3. McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998;16:2825-33.
4. Czuczman MS, Grillo-Lopez AJ, White CA, Saleh M, Gordon L, LoBuglio AF, et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 1999;17:268-76.
5. Olivieri A, Brunori M, Capelli D, Montanari M, Massidda D, Gini G, et al. Salvage therapy with an outpatient DHAP schedule followed by PBSC transplantation in 79 lymphoma patients: an intention to mobilize and transplant analysis. Eur J Haematol 2004;72:10-7.
6. Hennessy BT, Hanrahan EO, Daly PA. Non-Hodgkin lymphoma: an update. Lancet Oncol 2004;5:341-53.
7. Scott SD. Rituximab: a new therapeutic monoclonal antibody for non-Hodgkin's lymphoma. Cancer Pract 1998;6:195-7.
8. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235-42.
9. Press OW, Eary JF, Badger CC, Martin PJ, Appelbaum FR, Levy R, et al. Treatment of refractory non-Hodgkin's lymphoma with radiolabelled MB-1 (anti-CD37) antibody. J Clin Oncol 1989;7:1027-38.
10. Kaminski MS, Fig LM, Zasadny KR, Koral KF, DelRosario RB, Francis IR, et al. Imaging, dosimetry, and radioimmunotherapy with iodine 131-labelled anti-CD37 antibody in B-cell lymphoma. J Clin Oncol 1992;10:1696-711.
11. Press OW, Eary JF, Appelbaum FR, Martin PJ, Badger CC, Nelp WB, et al. Radiolabelled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med 1993;329:1219-24.
12. Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, Emmanouilides C, Joyce R, et al. Randomized controlled trial of yttrium-90-labelled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 2002;20:2453-63.
13. Behr TM, Wormann B, Gramatzki M, Riggert J, Gratz S, Behe M, et al. Low- versus high-dose radioimmunotherapy with humanized anti-CD22 or chimeric anti-CD20 antibodies in a broad spectrum of B cell-associated malignancies. Clin Cancer Res 1999;5:3304s-14s.
14. Behr TM, Griesinger F, Riggert J, Gratz S, Behe M, Kaufmann CC, et al. High-dose myeloablative radioimmunotherapy of mantle cell non-Hodgkin lymphoma with the iodine-131-labelled chimeric anti-CD20 antibody C2B8 and autologous stem cell support. Results of a pilot study. Cancer 2002;94:1363-72.
15. 131I-labelled anti-CD20 MAB IDEC-C2B8 (rituximab) in relapsed non-Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging 2002;29:1276-82.
16. 131I-anti CD20 radioimmunotherapy of relapsed or refractory non-Hodgkin's lymphoma: a phase II clinical trial of a nonmyeloablative dose regimen of chimeric rituximab radiolabelled in a hospital. Cancer Biother Radiopharm 2003;18:513-24.
17. Behr TM, Gotthardt M, Becker W, Behe M. Radioiodination of monoclonal antibodies, proteins and peptides for diagnosis and therapy. A review of standardized, reliable and safe procedures for clinical grade levels kBq to GBq in the Gottingen/Marburg experience. Nuklearmedizin 2002;41:71-9.
18. Wahl RL, Wissing J, del Rosario R, Zasadny KR. Inhibition of autoradiolysis of radiolabelled monoclonal antibodies by cryopreservation. J Nucl Med 1990;31:84-9.
19. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999;17:1244.
20. Wahl RL, Zasadny KR, MacFarlane D, Francis IR, Ross CW, Estes J, et al. Iodine-131 anti-B1 antibody for B-cell lymphoma: an update on the Michigan Phase I experience. J Nucl Med 1998;39:21S-27S.
21. Kaminski MS, Zasadny KR, Francis IR, Fenner MC, Ross CW, Milik AW, et al. Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. J Clin Oncol 1996;14:1974-81.
22. Kaminski MS, Estes J, Zasadny KR, Francis IR, Ross CW, Tuck M, et al. Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood 2000;96:1259-66.
23. Witzig TE, White CA, Gordon LI, Wiseman GA, Emmanouilides C, Murray JL, et al. Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-Hodgkin's lymphoma. J Clin Oncol 2003;21:1263-70.
24. 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma. Eur J Nucl Med 2000;27:766-77.
25. 90Y-labelled anti-CD20 monoclonal antibody. Clin Cancer Res 1999;5:3281s-6s.
26. Witzig TE, Flinn IW, Gordon LI, Emmanouilides C, Czuczman MS, Saleh MN, et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol 2002;20:3262-9.
27. Press OW. Radiolabelled antibody therapy of B-cell lymphomas. Semin Oncol 1999;26:58-65.
28. Goldenberg DM. Advancing role of radiolabelled antibodies in the therapy of cancer. Cancer Immunol Immunother 2003;52:281-96.
29. Witzig TE, White CA, Wiseman GA, Gordon LI, Emmanouilides C, Raubitschek A, et al. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma. J Clin Oncol 1999;17:3793-803.
30. Bastion Y, Sebban C, Berger F, Felman P, Salles G, Dumontet C, et al. Incidence, predictive factors, and outcome of lymphoma transformation in follicular lymphoma patients. J Clin Oncol 1997;15:1587-94.
31. 131I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma. J Clin Oncol 1998;16:3246-56.
32. Nordoy T, Kolstad A, Tuck MK, Aaberge IS, Husebekk A, Kaminski MS. Radioimmunotherapy with iodine-131 tositumomab in patients with low-grade non-Hodgkin's B-cell lymphoma does not induce loss of acquired humoral immunity against common antigens. Clin Immunol 2001;100:40-8.
33. 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. Lancet 1995;346:336-40.
34. Liu SY, Eary JF, Petersdorf SH, Martin PJ, Maloney DG, Appelbaum FR, et al. Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labelled anti-CD20 antibody and autologous stem-cell rescue. J Clin Oncol 1998;16:3270-8.